Brookline Capital Markets Starts SQZ Biotechnologies (SQZ) at Buy
Tweet
Share
E-mailGet Alerts SQZ Hot Sheet
Price: $13.66 +1.04%
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 42
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 42
Trade Now!
Join SI Premium – FREE
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Brookline Capital Markets analyst Leah Rush Cann initiates coverage on SQZ Biotechnologies (NYSE: SQZ) with a Buy rating and a price target of $40.00.
The analyst commented, "We are initiating coverage of SQZ Biotech, a development-stage biotechnology company working in solid tumors cancers, autoimmune disease and infectious disease, with a Buy rating and a 12-18-month $40 target price."
For an analyst ratings summary and ratings history on SQZ Biotechnologies click here. For more ratings news on SQZ Biotechnologies click here.
Shares of SQZ Biotechnologies closed at $12.07 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Starts Olo Inc. (OLO) at Outperform
- Deutsche Post AG (DPW:GR) (DPSGY) PT Raised to EUR68.47 at JPMorgan
- ING (INGA:NA) (ING) PT Raised to EUR12 at Deutsche Bank
Create E-mail Alert Related Categories
Analyst Comments, Hot New Coverage, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
